+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Overactive Bladder Treatment Market Analysis by Pharmacotherapy, by Disease Type, and by Region - Global Forecast to 2029

  • PDF Icon

    Report

  • 135 Pages
  • September 2022
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5651389
The overactive bladder treatment market size is estimated to be USD 3.9 billion in 2021 and is expected to witness a CAGR of 5.63% during the forecast period 2022-2029. The development of novel intravenous medicines, active marketing by pharmaceutical companies, favourable demographics, increasing prevalence of diseases characterized by OAB, and growing geriatric population are some of the key drivers for the market growth. However, adverse effects of treatment are expected to restrain the market growth.

By Pharmacotherapy

Based on pharmacotherapy, the market is segregated into solifenacin, darifenacin, anticholinergics, oxybutynin, botox, mirabegron, tolterodine, neurostimulation, trospium, and fesoterodine. In 2021, the anticholinergics segment accounted for the highest revenue share due to minimal chance of adverse effects and dementia.

By Disease Type

On the basis of disease type, the market is categorized into neurogenic bladder overactivity and idiopathic bladder overactivity. In 2021, the idiopathic bladder overactivity segment accounted for the highest revenue share owing to the increased frequency of idiopathic overactive bladder conditions and rising usage of SNM treatment for individuals with idiopathic overactive bladder.

Regional Markets

In 2021, Europe region accounted for the highest revenue in the overactive bladder treatment market and is expected to maintain its dominance during the forecast period. This is attributed to its well-established healthcare industry, which offers advantageous reimbursement for overactive bladder therapy, and disease's rising numbers as people become older and the existence of large companies.

Competitor Insights

Some of the key players operating in the overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including pharmacotherapy and disease type from 2021 to 2029.

Segmentation: Overactive Bladder Treatment Market Report 2021-2029

By Pharmacotherapy (Revenue, USD Billion)

  • Solifenacin
  • Darifenacin
  • Anticholinergics
  • Oxybutynin
  • BOTOX
  • Mirabegron
  • Tolterodine
  • Neurostimulation
  • Trospium
  • Fesoterodine

By Disease Type (Revenue, USD Billion)

  • Neurogenic Bladder Overactivity
  • Idiopathic Bladder Overactivity

By Region (Revenue, USD Billion)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1.Study Objectives
1.2.Study Scope
1.3.Research Assumptions
1.4.Research Framework
1.4.1.Research Models
1.4.1.1.Bottom-up Approach
1.4.1.2.Top-down Approach
1.4.1.3.Data Triangulation
1.4.2.Data Procurement
1.4.2.1.Internal Database
1.4.2.2.Secondary Research
1.4.2.3.Purchased Database
1.4.2.4.Primary Research
1.4.3.Data Analysis
1.4.3.1.Data Validation
1.4.3.2.Market Size Estimation
1.4.3.3.Market Forecast Model
1.4.4.Quality Assessment
2. Introduction: Overactive Bladder Treatment
3. Executive Summary
3.1.Global Market Scenario
3.2.Segment Market Scenario
3.3.Geographic Market Scenario
3.4.COVID-19 Impact
3.5.Competitive Landscape
4. Market Dynamics
4.1. Market Drivers
4.1.1.Driver 1
4.1.2.Driver 2
4.1.3.Driver 3
4.1.4.Driver 4
4.1.5.Driver 5
4.2.Market Restraint
4.2.1.Restraint 1
4.2.2.Restraint 2
4.2.3.Restraint 3
4.2.4.Restraint 4
4.3.Market Opportunities
4.3.1.Opportunity 1
4.3.2.Opportunity 2
4.3.3.Opportunity 3
4.3.4.Opportunity 4
4.4.Market Trends
4.4.1.Trend 1
4.4.2.Trend 2
4.4.3.Trend 3
4.4.4.Trend 4
4.5.Market Challenges
4.5.1.Challenge 1
4.5.2.Challenge 2
4.5.3.Challenge 3
4.5.4.Challenge 4
5. Market Environment Analysis
5.1.Porter’s 5 Forces Analysis
5.2.PESTEL Analysis
5.3.Value Chain Analysis
5.4.SWOT Analysis
5.5.Benchmark
6. COVID-19 Impact Analysis: Overactive Bladder Treatment Market
6.1.COVID-19: Overview
6.2.COVID-19 Impact on the Global Market
6.3.COVID-19 Impact on the Regional Markets
7. Market Analysis by Pharmacotherapy
7.1.Solifenacin
7.1.1.Solifenacin Market Forecast, 2021-2029 (USD Million)
7.2.Darifenacin
7.2.1.Darifenacin Market Forecast, 2021-2029 (USD Million)
7.3.Anticholinergics
7.3.1.Anticholinergics Market Forecast, 2021-2029 (USD Million)
7.4.Oxybutynin
7.4.1.Oxybutynin Market Forecast, 2021-2029 (USD Million)
7.5.BOTOX
7.5.1.BOTOX Market Forecast, 2021-2029 (USD Million)
7.6.Mirabegron
7.6.1.Mirabegron Market Forecast, 2021-2029 (USD Million)
7.7.Tolterodine
7.7.1.Tolterodine Market Forecast, 2021-2029 (USD Million)
7.8.Neurostimulation
7.8.1.Neurostimulation Market Forecast, 2021-2029 (USD Million)
7.9.Trospium
7.9.1.Trospium Market Forecast, 2021-2029 (USD Million)
7.10.Fesoterodine
7.10.1.Fesoterodine Market Forecast, 2021-2029 (USD Million)
8. Market Analysis by Disease Type
8.1.Neurogenic Bladder Overactivity
8.1.1.Neurogenic Bladder Overactivity Market Forecast, 2021-2029 (USD Million)
8.2.Idiopathic Bladder Overactivity
8.2.1.Idiopathic Bladder Overactivity Market Forecast, 2021-2029 (USD Million)
9. Regional Market Analysis
9.1.Regional Market Trends
9.2.Regional Market: Comparative Analysis
10. North America Overactive Bladder Treatment Market
10.1.North America Overactive Bladder Treatment Market
10.1.1.North America Market Size and Forecast, 2021-2029 (USD Million)
10.1.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
10.1.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
10.2.U.S. Overactive Bladder Treatment Market
10.2.1.U.S. Market Size and Forecast, 2021-2029 (USD Million)
10.2.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
10.2.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
10.3.Canada Overactive Bladder Treatment Market
10.3.1.Canada Market Size and Forecast, 2021-2029 (USD Million)
10.3.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
10.3.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11. Europe Overactive Bladder Treatment Market
11.1.Europe Overactive Bladder Treatment Market
11.1.1.Europe Market Size and Forecast, 2021-2029 (USD Million)
11.1.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.1.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.2.Germany Overactive Bladder Treatment Market
11.2.1.Germany Market Size and Forecast, 2021-2029 (USD Million)
11.2.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.2.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.3.UK Overactive Bladder Treatment Market
11.3.1.UK Market Size and Forecast, 2021-2029 (USD Million)
11.3.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.3.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.4.France Overactive Bladder Treatment Market
11.4.1.France Market Size and Forecast, 2021-2029 (USD Million)
11.4.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.4.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.5.Spain Overactive Bladder Treatment Market
11.5.1.Spain Market Size and Forecast, 2021-2029 (USD Million)
11.5.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.5.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.6.Italy Overactive Bladder Treatment Market
11.6.1.Italy Market Size and Forecast, 2021-2029 (USD Million)
11.6.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.6.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
11.7.Rest of Europe Overactive Bladder Treatment Market
11.7.1.Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
11.7.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
11.7.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12. Asia Pacific Overactive Bladder Treatment Market
12.1.Asia Pacific Overactive Bladder Treatment Market
12.1.1.Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
12.1.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.1.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.2.Japan Overactive Bladder Treatment Market
12.2.1.Japan Market Size and Forecast, 2021-2029 (USD Million)
12.2.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.2.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.3.China Overactive Bladder Treatment Market
12.3.1.China Market Size and Forecast, 2021-2029 (USD Million)
12.3.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.3.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.4.India Overactive Bladder Treatment Market
12.4.1.India Market Size and Forecast, 2021-2029 (USD Million)
12.4.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.4.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.5.South Korea Overactive Bladder Treatment Market
12.5.1.South Korea Market Size and Forecast, 2021-2029 (USD Million)
12.5.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.5.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.6.Australia Overactive Bladder Treatment Market
12.6.1.Australia Market Size and Forecast, 2021-2029 (USD Million)
12.6.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.6.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
12.7.Rest of Asia Pacific Overactive Bladder Treatment Market
12.7.1.Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
12.7.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
12.7.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
13. Latin America Overactive Bladder Treatment Market
13.1.Latin America Overactive Bladder Treatment Market
13.1.1.Latin America Market Size and Forecast, 2021-2029 (USD Million)
13.1.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
13.1.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
13.2.Brazil Overactive Bladder Treatment Market
13.2.1.Brazil Market Size and Forecast, 2021-2029 (USD Million)
13.2.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
13.2.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
13.3.Mexico Overactive Bladder Treatment Market
13.3.1.Mexico Market Size and Forecast, 2021-2029 (USD Million)
13.3.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
13.3.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
13.4.Argentina Overactive Bladder Treatment Market
13.4.1.Argentina Market Size and Forecast, 2021-2029 (USD Million)
13.4.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
13.4.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
13.5.Rest of Latin America Overactive Bladder Treatment Market
13.5.1.Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
13.5.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
13.5.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
14. MEA Overactive Bladder Treatment Market
14.1.MEA Overactive Bladder Treatment Market
14.1.1.MEA Market Size and Forecast, 2021-2029 (USD Million)
14.1.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
14.1.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
14.2.GCC Overactive Bladder Treatment Market
14.2.1.GCC Market Size and Forecast, 2021-2029 (USD Million)
14.2.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
14.2.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
14.3.South Africa Overactive Bladder Treatment Market
14.3.1.South Africa Market Size and Forecast, 2021-2029 (USD Million)
14.3.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
14.3.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
14.4.Rest of MEA Overactive Bladder Treatment Market
14.4.1.Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
14.4.1.1.Market Size and Forecast by Pharmacotherapy, 2021-2029 (USD Million)
14.4.1.2.Market Size and Forecast by Disease Type, 2021-2029 (USD Million)
15. Competitor Analysis
15.1.Market Share Analysis, 2021 & 2029
15.2.Competitive Mapping
15.3.Key Players Market Place Analysis
15.4.Major Recent Developments
16. Company Profiles
16.1.Astellas Pharma, Inc. (Japan)
16.1.1.Company Snapshot
16.1.2.Company Overview
16.1.3.Financials
16.1.4.Pharmacotherapy Benchmarking
16.1.5.Recent Developments
16.2.Pfizer, Inc. (U.S.)
16.2.1.Company Snapshot
16.2.2.Company Overview
16.2.3.Financials
16.2.4.Pharmacotherapy Benchmarking
16.2.5.Recent Developments
16.3.Teva Pharmaceutical Industries Limited (Israel)
16.3.1.Company Snapshot
16.3.2.Company Overview
16.3.3.Financials
16.3.4.Pharmacotherapy Benchmarking
16.3.5.Recent Developments
16.4.Allergan, Plc (Ireland)
16.4.1.Company Snapshot
16.4.2.Company Overview
16.4.3.Financials
16.4.4.Pharmacotherapy Benchmarking
16.4.5.Recent Developments
16.5.Medtronic plc (Ireland)
16.5.1.Company Snapshot
16.5.2.Company Overview
16.5.3.Financials
16.5.4.Pharmacotherapy Benchmarking
16.5.5.Recent Developments
16.6.Mylan N.V. (U.S.)
16.6.1.Company Snapshot
16.6.2.Company Overview
16.6.3.Financials
16.6.4.Pharmacotherapy Benchmarking
16.6.5.Recent Developments
16.7. Endo International plc (Ireland)
16.7.1.Company Snapshot
16.7.2.Company Overview
16.7.3.Financials
16.7.4.Pharmacotherapy Benchmarking
16.7.5.Recent Developments
16.8.Hisamitsu Pharmaceutical Co., Inc. (Japan)
16.8.1.Company Snapshot
16.8.2.Company Overview
16.8.3.Financials
16.8.4.Pharmacotherapy Benchmarking
16.8.5.Recent Developments
16.9.Sanofi (France)
16.9.1.Company Snapshot
16.9.2.Company Overview
16.9.3.Financials
16.9.4.Pharmacotherapy Benchmarking
16.9.5.Recent Developments
16.10.Aurobindo Pharma Limited (India)
16.10.1.Company Snapshot
16.10.2.Company Overview
16.10.3.Financials
16.10.4.Pharmacotherapy Benchmarking
16.10.5.Recent Developments
16.11. Apotex, Inc. (Canada)
16.11.1.Company Snapshot
16.11.2.Company Overview
16.11.3.Financials
16.11.4.Pharmacotherapy Benchmarking
16.11.5.Recent Developments
16.12.Cogentix Medical, Inc. (U.S.)
16.12.1.Company Snapshot
16.12.2.Company Overview
16.12.3.Financials
16.12.4.Pharmacotherapy Benchmarking
16.12.5.Recent Developments
16.13.Company 13
16.13.1.Company Snapshot
16.13.2.Company Overview
16.13.3.Financials
16.13.4.Pharmacotherapy Benchmarking
16.13.5.Recent Developments
16.14.Company 14
16.14.1.Company Snapshot
16.14.2.Company Overview
16.14.3.Financials
16.14.4.Pharmacotherapy Benchmarking
16.14.5.Recent Developments
16.15. Company 15
16.15.1.Company Snapshot
16.15.2.Company Overview
16.15.3.Financials
16.15.4.Pharmacotherapy Benchmarking
16.15.5.Recent Developments
16.16.Others Prominent Players
17. Conclusion & Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc. (Japan)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Allergan
  • Plc (Ireland)
  • Medtronic plc (Ireland)
  • Mylan N.V. (U.S.)
  • Endo International plc (Ireland)
  • Hisamitsu Pharmaceutical Co. Inc. (Japan)
  • Sanofi (France)
  • Aurobindo Pharma Limited (India)
  • Apotex Inc. (Canada)
  • Cogentix Medical Inc. (U.S.).